These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Ito T; Handa H Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676 [TBL] [Abstract][Full Text] [Related]
11. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival. Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104 [TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanisms of the Teratogenic Effects of Thalidomide. Asatsuma-Okumura T; Ito T; Handa H Pharmaceuticals (Basel); 2020 May; 13(5):. PubMed ID: 32414180 [TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of Cereblon via suppression of the TRIF/IRF3 pathway. Millrine D; Miyata H; Tei M; Dubey P; Nyati K; Nakahama T; Gemechu Y; Ripley B; Kishimoto T Int Immunol; 2016 Jun; 28(6):307-15. PubMed ID: 26865412 [TBL] [Abstract][Full Text] [Related]
14. [Recent topics in IMiDs and cereblon]. Ito T; Handa H Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850 [TBL] [Abstract][Full Text] [Related]
15. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related]
16. Structural dynamics of the cereblon ligand binding domain. Hartmann MD; Boichenko I; Coles M; Lupas AN; Hernandez Alvarez B PLoS One; 2015; 10(5):e0128342. PubMed ID: 26024445 [TBL] [Abstract][Full Text] [Related]
17. Identification of a primary target of thalidomide teratogenicity. Ito T; Ando H; Suzuki T; Ogura T; Hotta K; Imamura Y; Yamaguchi Y; Handa H Science; 2010 Mar; 327(5971):1345-50. PubMed ID: 20223979 [TBL] [Abstract][Full Text] [Related]
18. Structural basis of thalidomide enantiomer binding to cereblon. Mori T; Ito T; Liu S; Ando H; Sakamoto S; Yamaguchi Y; Tokunaga E; Shibata N; Handa H; Hakoshima T Sci Rep; 2018 Jan; 8(1):1294. PubMed ID: 29358579 [TBL] [Abstract][Full Text] [Related]
19. mRNA distribution of the thalidomide binding protein cereblon in adult mouse brain. Aizawa M; Abe Y; Ito T; Handa H; Nawa H Neurosci Res; 2011 Apr; 69(4):343-7. PubMed ID: 21241746 [TBL] [Abstract][Full Text] [Related]
20. Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production. Millrine D; Tei M; Gemechu Y; Kishimoto T Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10625-30. PubMed ID: 27601648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]